drugset / Trial / NCT02915042

Dexmedetomidine vs Placebo for Pediatric Cleft Palate Repair

NCT02915042 ↗

Phase 4 Withdrawn Baylor College of Medicine
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of administering intravenous dexmedetomidine as a single preemptive dose to placebo in reducing the total 24 hour dose of opioids as measured on a weight adjusted morphine equivalent basis.

Timeline

Start
2017-12-31
Primary completion
2019-12
Completion
2019-12

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment concerns”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 1 ug/kg Intravenous

Indications